Abstract
High intensity focused ultrasound (HIFU) rapidly and non-invasively destroys tumor tissue. Here, we sought to assess the immunomodulatory effects of MR-guided HIFU and its combination with the innate immune agonist CpG and checkpoint inhibitor anti-PD-1. Mice with multi-focal breast cancer underwent ablation with a parameter set designed to achieve mechanical disruption with minimal thermal dose or a protocol in which tumor temperature reached 65 °C. Mice received either HIFU alone or were primed with the toll-like receptor 9 agonist CpG and the checkpoint modulator anti-PD-1. Both mechanical HIFU and thermal ablation induced a potent inflammatory response with increased expression of Nlrp3, Jun, Mefv, Il6 and Il1β and alterations in macrophage polarization compared to control. Furthermore, HIFU upregulated multiple innate immune receptors and immune pathways, including Nod1, Nlrp3, Aim2, Ctsb, Tlr1/2/4/7/8/9, Oas2, and RhoA. The inflammatory response was largely sterile and consistent with wound-healing. Priming with CpG attenuated Il6 and Nlrp3 expression, further upregulated expression of Nod2, Oas2, RhoA, Pycard, Tlr1/2 and Il12, and enhanced T-cell number and activation while polarizing macrophages to an anti-tumor phenotype. The tumor-specific antigen, cytokines and cell debris liberated by HIFU enhance response to innate immune agonists.
Original language | English |
---|---|
Article number | 927 |
Journal | Scientific Reports |
Volume | 11 |
Issue number | 1 |
DOIs | |
State | Published - 13 Jan 2021 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2021, The Author(s).
Funding
The authors wish to thank Ms. Stephenie Y. Liu of the UC Davis Comprehensive Cancer Center (UCDCCC) Genomics Shared Resource (GSR) for her expert technical assistance. The UC Davis Comprehensive Cancer Center Genomics Shared Resource is supported by Cancer Center Support Grant P30CA093373 awarded by the NCI. The authors also wish to thank Meredith Weglarz, Lisa Nichols, and Ricardo Zermeno of the Stanford Shared FACS Facility for their guidance in panel construction and analysis. We acknowledge the support of R01CA210553, R01CA253316, and T32GM007276.
Funders | Funder number |
---|---|
National Institutes of Health | |
National Cancer Institute | T32GM007276, R01CA253316, R01CA210553 |
Office of Extramural Research, National Institutes of Health | |
University of California, Davis | P30CA093373 |
Office of Research Infrastructure Programs, National Institutes of Health |